Answers are grounded in this paper and cite their sources.
Results of this trial suggest a benefit for EGFR/HER1 blockade with erlotinib in patients with HCC manifested by disease control. Additional studies with erlotinib as a single agent or in combination with other agents are warranted.
No takes yet. Share an insight, caveat, or question.
Philip et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: